UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
__________________________________
Date of Report (Date of earliest event reported): April 26, 2022
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of principal executive offices) | (Zip Code) | ||||
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
1
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
2
| Item 2.02 | Results of Operations and Financial Condition. | ||||
On April 26, 2022, NeuroMetrix, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2022. The full text of the press release and the related attachment are furnished as Exhibit 99.1 hereto and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. | ||||
(d)Exhibits.
Exhibit No. Description
99.1 Press Release of NeuroMetrix, Inc. dated April 26, 2022.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEUROMETRIX, INC. | |||||||||||
| Date: April 26, 2022 | /s/ | THOMAS T. HIGGINS | |||||||||
| Thomas T. Higgins | |||||||||||
| Senior Vice President, Chief Financial Officer | |||||||||||
| and Treasurer | |||||||||||
4
EXHIBIT INDEX
| Exhibit No. | Description | |||||||
| Press Release of NeuroMetrix, Inc. dated April 26, 2022 | ||||||||
5
NeuroMetrix Reports Q1 2022 Financial Results
WOBURN, Mass., April 26, 2022 (Globe NewsWire) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.
Highlights:
•Q1 2022 revenue of $2.3 million increased by 6.8% from $2.2 million in the prior year. DPNCheck® sales into Medicare Advantage were the primary contributor to revenue and posted 15.6% year-on-year growth. The gross margin rate was 77.9% in Q1 2022 versus 73.3% in Q1 2021.
•Operating expenses were $2.8 million versus $1.6 million in Q1 2021. Sales & marketing and general & administrative spending increased to support the Company's growth initiatives. Also, prior year R&D expenses benefited from the reversal of a previously accrued technology fee of $450 thousand.
•Net loss for the quarter was $959 thousand or ($0.14) per share
•The Company ended the quarter with cash and equivalents of $23.8 million
•In January the Company’s Quell® technology received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for treatment of chronic chemotherapy induced peripheral neuropathy (CIPN).
•The Company's value-based health care commercial team grew to 4 uniquely experienced sales, marketing and clinical leaders.
"Our value-based care commercial team is now fully trained and focused on building our DPNCheck® Medicare Advantage business. Although the sales cycle is long, they have had impressive success engaging existing and prospective customers," said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. “We are also encouraged by progress in our Quell prescription neurotherapeutics platform. We are interacting with the FDA on the fibromyalgia De Novo request and monitoring randomized controlled trials evaluating potential new indications including CIPN and post-acute sequalae of COVID (long COVID).”
Financials:
Q1 2022 revenue of $2.30 million increased by $147 thousand or 6.82% over the prior year. Gross margin of $1.79 million improved by $214 thousand or 13.6% over Q1 2021. Operating expenses of $2.76 million increased by $1.12 million from $1.64 million in Q1 2021. Sales and marketing costs included $0.39 million in new spending related to development of the value-based healthcare commercial team. General and administrative costs reflected $150 thousand primarily due to restoration of management compensation. R&D expenses in 2021 benefited from reversal of a previously accrued technology fee of $450 thousand. The net loss for Q1 2022 was $959 thousand or ($0.14) per share.
Company to Host Live Conference Call and Webcast
NeuroMetrix will host a conference call at 8:00 a.m. Eastern today, April 26, 2022. The call may be accessed in the United States at 844-787-0799, international at 661-378-9630 using confirmation code 5754338. A replay will be available starting two hours after the call at 855-859-2056 United States and 404-537-3406 international using confirmation code 5754338. It will remain available for one week. The call will also be webcast and accessible at www.NeuroMetrix.com under "Investor Relations".
About NeuroMetrix
NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the
1
evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of lower extremity chronic pain that is available over-the-counter. For more information, visit www.NeuroMetrix.com.
Safe Harbor Statement
The statements contained in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the company’s or management’s expectations regarding the business, as well as events that could have a meaningful impact on the company’s revenues and cash resources. While the company believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements, including, without limitation, the effects of the COVID-19 pandemic on all aspects of the Company’s business, estimates of future performance, and the ability to successfully develop, receive regulatory clearance, commercialize and achieve market acceptance for any products. There can be no assurance that future developments will be those that the company has anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, as well as other documents that may be filed from time to time with the Securities and Exchange Commission or otherwise made public. The company is providing the information in this press release only as of the date hereof, and expressly disclaims any intent or obligation to update the information included in this press release or revise any forward-looking statements.
Source: NeuroMetrix, Inc.
Thomas T. Higgins
SVP and Chief Financial Officer
781-314-2761
neurometrix.ir@neurometrix.com
2
NeuroMetrix, Inc.
Statements of Operations
(Unaudited)
Quarters Ended March 31, | ||||||||||||||||||||||||||
2022 | 2021 | |||||||||||||||||||||||||
Revenues | $ | 2,302,391 | $ | 2,155,472 | ||||||||||||||||||||||
Cost of revenues | 508,874 | 576,289 | ||||||||||||||||||||||||
Gross profit | 1,793,517 | 1,579,183 | ||||||||||||||||||||||||
Operating expenses: | ||||||||||||||||||||||||||
Research and development | 710,577 | 233,277 | ||||||||||||||||||||||||
Sales and marketing | 858,839 | 393,825 | ||||||||||||||||||||||||
General and administrative | 1,186,091 | 1,012,276 | ||||||||||||||||||||||||
Total operating expenses | 2,755,507 | 1,639,378 | ||||||||||||||||||||||||
Loss from operations | (961,990 | ) | (60,195 | ) | ||||||||||||||||||||||
Other income | 3,428 | 412 | ||||||||||||||||||||||||
Net loss | $ | (958,562 | ) | $ | (59,783 | ) | ||||||||||||||||||||
NeuroMetrix, Inc.
Condensed Balance Sheets
(Unaudited)
March 31, 2022 | December 31, 2021 | |||||||||||||||||||||||||
Cash and cash equivalents | $ | 23,769,380 | $ | 22,572,104 | ||||||||||||||||||||||
Other current assets | 1,817,871 | 1,615,755 | ||||||||||||||||||||||||
Noncurrent assets | 661,120 | 700,333 | ||||||||||||||||||||||||
Total assets | $ | 26,248,371 | $ | 24,888,192 | ||||||||||||||||||||||
Current liabilities | $ | 1,727,254 | $ | 1,365,697 | ||||||||||||||||||||||
Lease obligation, net of current portion | 283,209 | 306,709 | ||||||||||||||||||||||||
| Stockholders’ equity | 24,237,908 | 23,215,786 | ||||||||||||||||||||||||
| Total liabilities and stockholders’ equity | $ | 26,248,371 | $ | 24,888,192 | ||||||||||||||||||||||
3